This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00413699
First received: December 18, 2006
Last updated: May 1, 2017
Last verified: May 2017
  Purpose

The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are eligible for this study only after participating in another "qualifying" study of CP-690,550

A sub-study will be conducted within the A3921024 study, this study will evaluate the immune response to pneumococcal and influenza vaccines in patients receiving CP-690,550


Condition Intervention Phase
Arthritis, Rheumatoid Drug: CP-690,550 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Long-Term, Open-Label Follow-Up Study Of Tofacitinib (CP-690,550) For Treatment Of Rheumatoid Arthritis

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Primary endpoints will be standard laboratory safety data (chemistry, hematology, etc.) and adverse event (AE) reports [ Time Frame: Every visit until last observation ]
  • The long-term safety and tolerability of CP-690,550 5 mg BID and 10 mg BID for the treatment of rheumatoid arthritis [ Time Frame: Every visit until last observation ]

Secondary Outcome Measures:
  • Percent of patients with ACR 20, 50, and 70 responses [ Time Frame: Every visit until last observation. ]
  • Area under ACR n curve [ Time Frame: Every visit until last observation. ]
  • DAS 28 (CRP) and DAS 28 (ESR)as well as incidence of Disease Activity Score <2.6 and <3.2 [ Time Frame: Every visit until last observation. ]
  • HAQ DI score [ Time Frame: Every visit until last observation. ]
  • SF 36 score [ Time Frame: Every visit until last observation. ]
  • FACIT Fatigue Scale, EuroQol EQ 5D, Work Limitations Questionnaire, and RA Healthcare Resource Utilization Questionnaire [ Time Frame: Every visit until last observation. ]
  • Preservation of joint structure in patients who had baseline radiographs obtained in their qualifying index study [ Time Frame: Every 6 months until last observation. ]
  • Vaccine sub-study endpoints: 1. % achieving a satisfactory humoral response to the pneumococcal vaccine as defined by ≥ 2-fold increase in antibody concentrations [ Time Frame: at vaccine substudy visit 2 and 4 ]
  • Vaccine sub-study 2. % achieving a satisfactory humoral response to the seasonal influenza vaccine as defined by ≥ 4-fold increase in antibody titers [ Time Frame: at vaccine substudy visit 2 and 4 ]
  • 1. Percentage of subjects achieving protective antibody titers to the seasonal influenza vaccine as measured by a hemagglutination inhibition (HI) assay titer of ≥ 1:40 in ≥ 2 of 3 influenza antigens measured at vaccine sub-study [ Time Frame: at visit 2 and 4 ]
  • 2. Percentage of subjects who respond to each of the 12 pneumococcal antigens as defined by ≥ 2-fold increase in antibody concentrations from vaccine sub-study visit 2 (vaccination baseline) measured at vaccine sub-study visit 4 [ Time Frame: at visit 2 and 4 ]
  • 3. Percentage of subjects who respond to each of the 3 influenza antigens as defined by ≥ 4-fold increase in antibody titers from vaccine sub-study visit 2 (vaccination baseline) measured at vaccine sub-study visit 4 [ Time Frame: at visit 2 and 4 ]
  • 4. Fold increase of anti-pneumococcal antibody levels to each of the 12 pneumococcal antigens above vaccination baseline values (vaccine sub-study visit 2) at vaccine sub-study visit 4 [ Time Frame: at visit 2 and 4 ]
  • 5. Fold increase of anti-influenza antibody levels to each of the 3 influenza antigens above vaccination baseline values (vaccine sub-study visit 2) at vaccine sub-study visit 4 [ Time Frame: at visit 2 and 4 ]
  • 6. Concentrations of anti-pneumococcal antibodies at vaccine sub-study visit 3 and 4 [ Time Frame: at visit 3 and 4 ]
  • 7. Titers of anti-influenza antibodies at vaccine sub-study visit 3 and 4 [ Time Frame: at visit 3 and 4 ]

Estimated Enrollment: 4500
Actual Study Start Date: February 5, 2007
Estimated Study Completion Date: December 31, 2018
Primary Completion Date: November 30, 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Open-Label Active Treatment Enrolled from Phase 2
Patients enrolling from Phase 2 studies
Drug: CP-690,550
5 mg PO BID open label; may increase to 10 mg PO BID to provide greater control of RA if no related AEs are present. May be off study drug temporarily for up to 28 days for mild to moderate AEs.
Experimental: Open-Label Active Treatment Enrolled from Phase 3
Patients enrolling from Phase 3 studies
Drug: CP-690,550
10 mg PO BID open label; may decrease to 5 mg PO BID for mild to moderate AEs. May be off study drug temporarily for up to 28 days for mild to moderate AEs.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects who have participated in a randomized "qualifying" study of CP-690,550 for the treatment of rheumatoid arthritis

Vaccine sub-study visit

  • Subjects actively participating in Study A3921024 must have completed at least 3 months of continuous 10 mg BID CP-690,550 treatment in A3921024 as defined by >80% compliance with prescribed dose consumption of CP-690,550 over the previous 3 months.

Exclusion Criteria:

  • Serious medical conditions that would make treatment with CP-690,550 potentially unsafe

Vaccine sub-study visit

  1. Any documented influenza or pneumococcal infection within the last 3 months prior to randomization in this study
  2. Received any vaccine within 1 month prior to randomization in this study
  3. Received an influenza vaccine within 6 months or a pneumococcal vaccine within 5 years of randomization in this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00413699

  Show 476 Study Locations
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00413699     History of Changes
Other Study ID Numbers: A3921024
2006-005035-19 ( EudraCT Number )
Study First Received: December 18, 2006
Last Updated: May 1, 2017

Keywords provided by Pfizer:
long-term
open-label
safety

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Tofacitinib
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 22, 2017